Skip to content

CT-guided ozone-mediated lumbar sympathetic denervation (OL-SDN) in patients with resistant hypertension (RH)

CT-guided ozone-mediated lumbar sympathetic denervation in patients with resistant hypertension

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300071375
Enrollment
Unknown
Registered
2023-05-12
Start date
2022-08-01
Completion date
Unknown
Last updated
2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Resistant Hypertension

Interventions

Resistant hypertension:ozone-mediated lumbar sympathetic denervation (OL-SDN)

Sponsors

Jinan University affiliated Guangzhou Red Cross Hosptal
Lead Sponsor

Eligibility

Sex/Gender
All
Age
43 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Written informed consent must be obtained before any assessment is performed. 2.Male and female patients, age 18 to 80 years inclusive 3.Confirmed diagnosis of resistant hypertension (RH) in accordance with the American Heart Association scientific statement, i.e.to have a mean systolic blood pressure of =130 mmHg on 24-hour ambulatory blood pressure monitoring and/or =135 mm Hg during the day time hours, while taking maximally tolerated doses of at least three antihypertensive agents including a diuretic; or to have a controlled blood pressure with four or more antihypertensive agents.

Exclusion criteria

Exclusion criteria: 1.Patients with confirmed secondary hypertension (all-caused renal artery stenosis; adrenal pheochromocytoma; cushing disease; primary hyperaldosteronism; occluded sleep apnea syndrome (OSAS) ). 2.Patients with spine malformation, spine infective disease. 3.Patients with history of renal artery angioplasty or denervation. 4.Patients with history of lumber internal vertebra disc frequency ablation and sympathetic blockage. 5.Myocardial infarction / Cerebral Vascular Accident (CVA) / TIA within the past three months prior to enrollment.

Design outcomes

Primary

MeasureTime frame
Change in 24-hour ambulatory SBP (from baseline to 12 weeks);

Secondary

MeasureTime frame
Reduction in category numbers of anti-hypertensive drugs;Control rate of home BP ;Incidence of AEs;

Countries

China

Contacts

Public ContactLi Li

Jinan University, Guangzhou Red Cross Hospital

lilygs@126.com+86 189 2890 0300

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 8, 2026